Scientists develop new cancer-killing compound from salad plant

October 13, 2008,

( -- Researchers at the University of Washington have updated a traditional Chinese medicine to create a compound that is more than 1,200 times more specific in killing certain kinds of cancer cells than currently available drugs, heralding the possibility of a more effective chemotherapy drug with minimal side effects.

The new compound puts a novel twist on the common anti-malarial drug artemisinin, which is derived from the sweet wormwood plant (Artemisia annua L). Sweet wormwood has been used in herbal Chinese medicine for at least 2,000 years, and is eaten in salads in some Asian countries.

The scientists attached a chemical homing device to artemisinin that targets the drug selectively to cancer cells, sparing healthy cells. The results were published online Oct. 5 in the journal Cancer Letters.

"The compound is like a special agent planting a bomb inside the cell," said Tomikazu Sasaki, chemistry professor at UW and senior author of the study.

In the study, the UW researchers tested their artemisinin-based compound on human leukemia cells. It was highly selective at killing the cancer cells. The researchers also have preliminary results showing that the compound is similarly selective and effective for human breast and prostate cancer cells, and that it effectively and safely kills breast cancer in rats, Sasaki said.

Cancer drug designers are faced with the unique challenge that cancer cells develop from our own normal cells, meaning that most ways to poison cancer cells also kill healthy cells. Most available chemotherapies are very toxic, destroying one normal cell for every five to 10 cancer cells killed, Sasaki said. This is why chemotherapy's side effects are so devastating, he said.

"Side effects are a major limitation to current chemotherapies," Sasaki said. "Some patients even die from them."

The compound Sasaki and his colleagues developed kills 12,000 cancer cells for every healthy cell, meaning it could be turned into a drug with minimal side effects. A cancer drug with low side effects would be more effective than currently available drugs, since it could be safely taken in higher amounts.

The artemisinin compound takes advantage of cancer cell's high iron levels. Artemisinin is highly toxic in the presence of iron, but harmless otherwise. Cancer cells need a lot of iron to maintain the rapid division necessary for tumor growth.

Since too much free-floating iron is toxic, when cells need iron they construct a special protein signal on their surfaces. The body's machinery then delivers iron, shielded with a protein package, to these signals proteins. The cell then swallows this bundle of iron and proteins.

Artemisinin alone is fairly effective at killing cancer cells. It kills approximately 100 cancer cells for every healthy cell, about ten times better than current chemotherapies. To improve those odds, the researchers added a small chemical tag to artemisinin that sticks to the "iron needed here" protein signal. The cancer cell, unaware of the toxic compound lurking on its surface, waits for the protein machinery to deliver iron molecules and engulfs everything -- iron, proteins and toxic compound.

Once inside the cell, the iron reacts with artemisinin to release poisonous molecules called free radicals. When enough of these free radicals accumulate, the cell dies.

"The compound is like a little bomb-carrying monkey riding on the back of a Trojan horse," said Henry Lai, UW bioengineering professor and co-author of the study.

The compound is so selective for cancer cells partly due to their rapid multiplication, which requires high amounts of iron, and partly because cancer cells are not as good as healthy cells at cleaning up free-floating iron.

"Cancer cells get sloppy at maintaining free iron, so they are more sensitive to artemisinin," Sasaki said.

Cancer cells are already under significant stress from their high iron contents and other imbalances, Sasaki said. Artemisinin tips them over the edge. The compound's modus operandi also means it should be general for almost any cancer, the researchers said.

"Most currently available drugs are targeted to specific cancers," Lai said. "This compound works on a general property of cancer cells, their high iron content."

The compound is currently being licensed by the University of Washington to Artemisia Biomedical Inc., a company Lai, Sasaki and Narendra Singh, UW associate professor of bioengineering, founded in Newcastle, Wash. for development and commercialization. Human trials are at least several years away. Artemisinin is readily available, Sasaki said, and he hopes their compound can eventually be cheaply manufactured to help cancer patients in developing countries.

Other authors of the study are Steve Oh, UW medical student; Byung Ju Kim, UW chemistry instructor; and Singh.

The Washington Technology Center and the Witmer Foundation provided funding for the study.

Provided by University of Washington

Explore further: Iron removal as a potential cancer therapy

Related Stories

Iron removal as a potential cancer therapy

February 27, 2018
Researchers at Okayama University report in Oncotarget a promising method for targeting cancer stem cells that cause tumor growth and cancer relapse. The approach involves administering molecules that capture iron, an overload ...

You're less likely to get a blood transfusion now

February 27, 2018
(HealthDay)— Americans are getting fewer blood transfusions, and that's good news, researchers say.

Data detectives shift suspicions in Alzheimer's to inside villain

February 20, 2018
The mass pursuit of a conspicuous suspect in Alzheimer's disease may have encumbered research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer's studies encourages researchers ...

Pregnant women deficient in vitamin D may give birth to obese children

February 13, 2018
Vitamin D deficiency in pregnant women could preprogram babies to grow into obese children and adults, according to a Keck School of Medicine of USC-led study.

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

Researchers use magnets to cause programmed cancer cell deaths

October 8, 2012
(—A team of researchers in South Korea has developed a method to cause cell death in both living fish and lab bowel cancer cells (in vivo and in vitro) using a magnetic field. The application of the magnetic field, ...

Recommended for you

More than 2,500 cancer cases a week could be avoided

March 23, 2018
More than 135,500 cases of cancer a year in the UK could be prevented through lifestyle changes, according to new figures from a Cancer Research UK landmark study published today.

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Researchers examine role of fluid flow in ovarian cancer progression

March 22, 2018
New research from Virginia Tech is moving physicians closer to pinpointing a predictor of ovarian cancer, which could lead to earlier diagnosis of what is know as the "silent killer."

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Oct 14, 2008
Why can't such compounds bypass the normal clinical trials for people with advanced cancers, in the way AIDS drugs are permitted to do?
not rated yet May 27, 2009
Just buy some, if your local chemist or healthfood shop doesn't stock it Google it and buy on line.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.